Onco-Innovations Initiates Key ADME Studies for ONC010

Vancouver, Canada — July 16, 2026 — Leads & Copy — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the commencement of critical absorption, distribution, metabolism, and excretion (ADME) studies for its lead drug candidate, ONC010. This follows up on a previous announcement from May 8, 2026.

ONC010 is a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor, and the newly initiated studies are designed to thoroughly characterize its pharmacokinetic and metabolic profile. This research is a vital step in supporting the ongoing IND-enabling development of the ONC010 program.

The initial focus of the ADME studies is on the metabolism of the active pharmaceutical ingredient (API) within ONC010. The data gathered from these studies are intended to be instrumental in informing various aspects of the Company's broader development strategy, including manufacturing activities, formulation optimization, toxicology studies, and future clinical translation. These studies are expected to add to the existing body of preclinical evidence that supports the progression of ONC010 towards clinical evaluation.

“Initiating these ADME studies represents another important step in our systematic advancement of ONC010. A thorough understanding of how a therapeutic candidate is absorbed, distributed, metabolized and eliminated is fundamental to successful drug development,” said Thomas O’Shaughnessy, Chief Executive Officer of Onco-Innovations.

These ADME studies are an integral part of Onco-Innovations’ comprehensive IND-enabling development program for ONC010. This program also encompasses manufacturing, formulation, safety assessments, and regulatory activities, all aimed at preparing the candidate for future clinical evaluation.

“ADME studies play a critical role in evaluating the clinical potential of an investigational oncology therapy. The data generated through this program are expected to provide valuable information to support dose selection, safety assessment and overall development planning. These studies will further strengthen the scientific foundation of the ONC010 program as we continue progressing toward clinical translation,” said Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations.

**About ONC010**

ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), which is identified as a key enzyme in DNA damage repair. The program is being developed to capitalize on vulnerabilities present in cancer cells that rely on DNA repair pathways. It is intended to offer a distinct therapeutic approach for patients battling difficult-to-treat malignancies.

**About Onco-Innovations Limited**

Onco-Innovations is a Canadian-based company dedicated to the research and treatment of cancer, with a specific focus on oncology. The company's mission is to advance cancer prevention and treatment through groundbreaking research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license for patented technology aimed at targeting solid tumors.

Source: Onco-Innovations Limited